Crossmark

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response

Crossref DOI link: https://doi.org/10.1186/s13075-019-1815-0

Published Online: 2019-01-18

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

de Moel, Emma C. https://orcid.org/0000-0002-8940-8330
Derksen, Veerle F. A. M.

Trouw, Leendert A.

Bang, Holger

Collée, Gerard

Lard, Leroy R.

Ramiro, Sofia

Huizinga, Tom W. J.

Allaart, Cornelia F.

Toes, René E. M.

van der Woude, Diane
Funding

Funding for this research was provided by:

ZonMw (436001001)
License Information

Text and Data Mining valid from 2019-01-18
More Information

Article History

Received: 15 October 2018

Accepted: 7 January 2019

First Online: 18 January 2019

Ethics approval and consent to participate

: This study was conducted with the approval of the regional ethics committee at Leiden University Medical Center. The IMPROVED study was approved by the Medical Ethics Committees of all participating hospitals. Informed consent was obtained from all participants.

: Not applicable.

: R.E.M.T., T.W.J.H., and L.A.T. are among the inventors of a patent on the use of carbamylated antigens for diagnosis. H.B. is an employee of Orgentec Diagnostika, which manufactures diagnostic anti-acetylated peptide antibody assays. All other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.